Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/7/?d=1Neue Studien: Europe PMCdeIn vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique.https://www.psoriasis-news.de/articles.html/1_articles/in-vivo-multiphoton-microscopy-of-psoriasis-a-new-diagnosis-and-therapeutic-monitoring-technique-r431/Background and objectivesPsoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.

Patients and methods

This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2).

Results

MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001).

Conclusions

MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.

Weiterlesen

]]>431Tue, 03 Feb 2026 08:49:23 +0000Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/clinical-proof-of-concept-for-small-molecule-mediated-inhibition-of-il-17-in-psoriasis-r430/Weiterlesen

]]>430Tue, 03 Feb 2026 08:49:23 +0000Early maladaptive schemas, emotion regulation, coping with stress, quality of life, and psychological symptoms in psoriasis disease.https://www.psoriasis-news.de/articles.html/1_articles/early-maladaptive-schemas-emotion-regulation-coping-with-stress-quality-of-life-and-psychological-symptoms-in-psoriasis-disease-r429/2 = .46). Findings suggest maladaptive emotion-focused coping as a key mechanism linking schemas to psoriasis outcomes, supporting integrated dermatological and psychological interventions.

Weiterlesen

]]>429Tue, 03 Feb 2026 08:49:23 +0000The path to interception in psoriatic disease: from conceptual clarity to clinical translation.https://www.psoriasis-news.de/articles.html/1_articles/the-path-to-interception-in-psoriatic-disease-from-conceptual-clarity-to-clinical-translation-r428/Weiterlesen

]]>428Tue, 03 Feb 2026 08:49:23 +0000Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/systemic-treatment-strategies-for-patients-with-psoriasis-and-psoriatic-arthritis-in-the-setting-of-ana-positivity-or-lupus-spectrum-disease-a-comprehensive-systematic-review-r427/Weiterlesen

]]>427Tue, 03 Feb 2026 08:49:23 +0000Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China.https://www.psoriasis-news.de/articles.html/1_articles/differential-clinical-factors-influencing-the-effectiveness-of-distinct-biologic-agents-in-psoriasis-insights-from-a-prospective-cohort-study-in-china-r426/Objective and designThis prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.

Subjects

Patients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.

Treatment

Guideline-recommended dosing; 3-month follow-up.

Methods

The primary endpoint was PASI90 response at 3 months. Multivariable logistic regression estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for clinical predictors of treatment response.

Results

A total of 717 patients were included in the analysis. In guselkumab-treated patients, obesity (aOR 0.22, 95% CI 0.06-0.78) and prior biologic exposure (aOR 0.22, 95% CI 0.06-0.75) were independently associated with reduced PASI90 response. Psoriatic arthritis predicted poorer response to ustekinumab (aOR 0.16, 95% CI 0.03-0.78). For secukinumab, male sex reduced the likelihood of PASI90 (aOR 0.47, 95% CI 0.23-0.96), whereas family history of psoriasis improved outcomes (aOR 2.20, 95% CI 1.10-4.42). In ixekizumab-treated patients, obesity (aOR 0.38, 95% CI 0.18-0.80) was a negative predictor, while family history (aOR 2.79, 95% CI 1.22-6.38) enhanced treatment response.

Conclusions

Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics.

Weiterlesen

]]>426Tue, 03 Feb 2026 08:49:23 +0000Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trialhttps://www.psoriasis-news.de/articles.html/1_articles/impact-of-treatment-interruption-on-the-efficacy-and-safety-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-a-post-hoc-analysis-of-a-phase-3-trial-r425/No abstract supplied.

Weiterlesen

]]>425Tue, 03 Feb 2026 08:49:23 +0000Do Nails Tell a Pulmonary Tale? A Cross-Sectional Study on Psoriasis and Pulmonary Hypertension Risk.https://www.psoriasis-news.de/articles.html/1_articles/do-nails-tell-a-pulmonary-tale-a-cross-sectional-study-on-psoriasis-and-pulmonary-hypertension-risk-r416/BackgroundPsoriasis is a systemic inflammatory disease associated with cardiopulmonary comorbidities. Nail psoriasis, quantified by the Nail Psoriasis Severity Index (NAPSI), is a marker of severe disease. While pulmonary arterial hypertension (PAH) is reported more frequently in psoriasis, the specific correlation between nail psoriasis severity and PAH remains underexplored.

Objective

To investigate the correlation between NAPSI scores and the presence or severity of PAH in patients with psoriasis.

Methods

A prospective, cross-sectional study was conducted at a tertiary care centre involving 100 patients with chronic plaque psoriasis (50 with and 50 without nail psoriasis). All participants underwent dermatological evaluation [Psoriasis Area and Severity Index (PASI) and NAPSI scoring], transthoracic echocardiography to estimate pulmonary artery systolic pressure (PASP), and measurement of inflammatory markers [C-reactive protein (CRP), IL-17, TNF-α]. PAH was defined as PASP > 35 mmHg. Statistical analyses included correlation tests, comparative analyses, and multivariate logistic regression.

Results

PAH was identified in 29% (n = 29) of patients, with a significantly higher prevalence in the nail psoriasis group (40% vs 18%, P = .01). Patients with PAH had higher mean NAPSI scores than those without (29.5 ± 13.4 vs 18.2 ± 10.6, P = .001). A moderate positive correlation was found between NAPSI scores and PASP (r = 0.44, P < .001). PASI scores and CRP levels were also significantly elevated in patients with PAH and correlated with PASP (r = 0.38, P = .001 and r = 0.41, P < .001, respectively).Multivariate analysis confirmed NAPSI score as an independent predictor of PAH [odds ratio (OR): 1.07/unit increase, 95% CI: 1.03-1.11, P = .002], after adjusting for confounders including PASI score and comorbidities. PASI (OR: 1.05, P = .01) and CRP (OR: 1.13, P = .008) were also independent predictors. Nail matrix involvement was more strongly associated with PAH than nail bed involvement (P = .03). Inflammatory markers (CRP, IL-17, TNF-α) were significantly elevated in patients with PAH.

Conclusion

NAPSI scores, PASI scores, and CRP levels are all significantly correlated with and independently predict PAH in patients with psoriasis. Assessment of nail psoriasis severity may serve as a valuable, noninvasive clinical tool to identify psoriasis patients at increased risk of pulmonary vascular complications, warranting further cardiological evaluation.

Weiterlesen

]]>416Sun, 25 Jan 2026 18:42:10 +0000Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest.https://www.psoriasis-news.de/articles.html/1_articles/outcomes-in-patients-with-psoriasis-following-apremilast-treatment-results-from-the-german-psoriasis-registry-psobest-r415/IntroductionThe German national psoriasis registry PsoBest collects long-term data on the effectiveness, safety, and tolerability of systemic treatments for psoriatic disease. Here, we describe patient characteristics and the safety and effectiveness of apremilast for the treatment of psoriatic disease in Germany based on data from PsoBest.

Methods

This was a descriptive analysis of observational data collected from PsoBest using cross-sectional (baseline characteristics) and longitudinal (outcomes, safety) designs. PsoBest recruits patients with moderate to severe plaque psoriasis or psoriatic arthritis who initiate a new systemic psoriasis treatment. Adverse events (AEs) and sociodemographic descriptors were reported for patients exposed to apremilast during the study period (safety cohort). Clinical and patient-reported outcomes were collected 3, 6, and 12 months after the initiation of apremilast monotherapy (outcomes cohort).

Results

From January 15, 2015 to June 30, 2020, 595 registry patients were exposed to apremilast; 417 were treated with apremilast monotherapy. Patients taking apremilast had a higher mean age and higher proportions of comorbidities such as cardiovascular or metabolic disease compared with those taking other nonbiologic systemic or biologic drugs. The most common nonserious AEs were drug ineffectiveness (14.1%), diarrhea (9.4%), nausea (7.1%), and headache (6.1%). The highest incidence rates of nonserious and serious AEs of special interest were for infections and infestations per system organ class (8.03/100 patient-years) and malignant or unspecified tumors (2.50/100 patient-years), respectively. Improvements in Dermatology Life Quality Index, patient-defined treatment benefits (Patient Benefit Index), body surface area, and Psoriasis Area and Severity Index were observed after 3, 6, and 12 months of apremilast treatment.

Conclusions

Patients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease.

Weiterlesen

]]>415Sun, 25 Jan 2026 18:42:10 +0000Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.https://www.psoriasis-news.de/articles.html/1_articles/evaluating-risankizumabs-long-term-effects-in-psoriasis-using-optical-coherence-tomography-r414/IntroductionPsoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surface Area (BSA) focus on evaluating visible symptoms and are limited in capturing underlying disease activity. Optical coherence tomography (OCT), a non-invasive imaging modality, offers real-time assessment of structural and vascular changes, providing valuable insights beyond the skin surface.

Methods

This sub-analysis of a prospective, single-center exploratory study included 22 patients with moderate-to-severe psoriasis treated with risankizumab. Clinical assessments (PASI, IGA, BSA) were conducted at baseline and weeks 2, 4, 16, 28, 40, and 52. OCT imaging performed at baseline and weeks 4, 16, and 52 evaluated epidermal thickness and vascular parameters (e.g., vessel density and diameter) in lesional and perilesional skin.

Results

By week 16, mean (95% confidence interval [CI]) PASI score decreased from 16.3 (11.6-21.1) at baseline to 3.5 (1.8-5.2), and BSA involvement from 24.7% (16.1-33.3) to 5.2% (1.9-8.4) (both p < 0.001). By week 52, 86.7%, 73.3%, and 40.0% of patients achieved PASI 75, 90, and 100, respectively, and 93.3% achieved IGA 0/1. OCT showed lesional reductions in epidermal thickness (- 37.4%), vessel density (- 26.6% Δ area under the curve [AUC]), and vessel diameter (- 59.5% ΔAUC) over the 52-week period. Notably, vascular changes also occurred in uninvolved perilesional skin.

Conclusion

Risankizumab improved both clinical and OCT parameters over 52 weeks, emphasizing the importance of long-term therapy with benefits extending beyond visible improvement. OCT emerged as a valuable tool for assessing deep (vascular) treatment response, thereby supporting a more comprehensive understanding of therapeutic outcomes in psoriasis.

Weiterlesen

]]>414Sun, 25 Jan 2026 18:42:10 +0000Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature.https://www.psoriasis-news.de/articles.html/1_articles/dual-biologic-therapy-in-a-patient-with-severe-psoriasis-and-psoriatic-arthritis-using-guselkumab-and-bimekizumab-a-case-report-and-review-of-the-literature-r413/Weiterlesen

]]>413Sun, 25 Jan 2026 18:42:10 +0000Exploration of shared gene signatures and molecular mechanisms between psoriasis and COVID-19: evidence from transcriptome data.https://www.psoriasis-news.de/articles.html/1_articles/exploration-of-shared-gene-signatures-and-molecular-mechanisms-between-psoriasis-and-covid-19-evidence-from-transcriptome-data-r412/No abstract supplied.

Weiterlesen

]]>412Sun, 25 Jan 2026 18:42:10 +0000Psychometric Evaluation of Patients With Atopic Dermatitis and Comparison With Patients With Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/psychometric-evaluation-of-patients-with-atopic-dermatitis-and-comparison-with-patients-with-psoriasis-r411/Atopic dermatitis and psoriasis are two dermatological diseases that affect the mental health of patients. The purpose of this research is to investigate the comparison of the psychometric characteristics of two groups of patients with psoriasis and atopic dermatitis respectively focusing on depression, personality, hostility and psychosomatic burden. Τhe sample was consisted by 100 patients with psoriasis and 40 patients with atopic dermatitis, respectively. Specific questionnaires were given for the psychometric evaluation of patients with atopic dermatitis and psoriasis. The Beck's Depression Inventory (BDI), the Eysenck Personality Questionnaire (EPQ) the Brief Symptom Inventory SCL-90 scale, and the HDHQ questionnaire (Psychometric Hostility and Direction of Hostility Questionnaire). Patients with atopic dermatitis have statistically significantly higher scores on the scale of somatization and paranoid ideation, while patients with psoriasis have statistically significantly higher scores on the scale of depression. On the personality scales, patients with atopic dermatitis have on average statistically significantly higher scores on the psychoticism scale and lower scores on the lying scale than the psoriatic patients. Patients with atopic dermatitis present statistically significantly higher scores on the scale of paranoid hostility than patients with psoriasis. Patients receiving medication as well as the interaction of disease group with receiving medication are statistically significantly related to the psychopathology index. Patients' scores on the psychotic scale of the EPQ are statistically significantly related to the duration of the illness and the patient group, gender and medication intake. The psychosocial effects of psoriasis and atopic dermatitis on patients' mental health are demonstrated in the present study based on patient scores on psychometric scales and psychopathology index.

Weiterlesen

]]>411Sun, 25 Jan 2026 18:42:10 +0000Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/incidence-rate-and-risk-factors-of-arrhythmias-in-patients-with-psoriatic-arthritis-r410/ObjectivesTo assess the incidence and risk factors for arrhythmias in patients with psoriatic arthritis (PsA).

Methods

We performed a cohort analysis of patients followed prospectively from 1994 to 2024. Participants were evaluated using standard protocols at 6-to-12-month intervals. The following events were assessed: (1) atrial tachyarrhythmia (including atrial fibrillation and supraventricular tachycardia); (2) ventricular tachyarrhythmia and (3) bradycardia/pacemaker. The cumulative incidence rate (CIR) of each arrhythmia was calculated. Cox proportional hazards models (reported as the current level HR (measured just prior to the event) and the adjusted mean HR) were fitted to assess the association between selected measures of PsA disease activity and the age of occurrence of arrhythmia events. Each model was adjusted for sex, PsA duration, cardiovascular risk factors and medications.

Results

A total of 1670 patients with PsA were analysed (80 atrial tachyarrhythmias, 17 bradyarrhythmias/pacemakers and 11 ventricular tachyarrhythmias). By age 70, the CIRs were 7.82%, 0.67% and 0.45% for atrial, ventricular and bradycardia, respectively. In multivariable analysis, remission/low versus high disease activity state was associated with lower risk of atrial tachyarrhythmia (current HR 0.49, 95% CI 0.26 to 0.92; adjusted mean HR 0.46, 95% CI 0.23 to 0.91). Similarly, a higher three-item Visual Analogue Scale (3-VAS) was associated with a higher risk of atrial tachyarrhythmia (current level HR 1.18, 95% CI 1.04 to 1.33; adjusted mean HR 1.22, 95% CI 1.04 to 1.44).

Conclusions

Higher PsA disease activity is associated with higher atrial tachyarrhythmia risk. These findings reinforce the importance of controlling inflammation in PsA to optimise cardiac health.

Weiterlesen

]]>410Sun, 25 Jan 2026 18:42:10 +0000Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review.https://www.psoriasis-news.de/articles.html/1_articles/role-of-real-world-evidence-from-patient-registries-for-psoriasis-in-decision-making-a-systematic-review-r409/IntroductionTreatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient's lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understanding of outcomes outside of a controlled clinical trial setting. This study thus characterises the design and measures used in real-world studies of psoriasis treatment from patient registries and assesses its use in informing clinical guidelines and reimbursement decisions.

Methods and analysis

A systematic literature review was conducted to identify real-world observational studies that used psoriasis registry data. PubMed and Embase were searched for English-language studies published between January 2018 and January 2023. To assess how real-world studies, clinical guidelines, and reimbursement and coverage reports have informed practice, treatment, and reimbursement guidelines, a narrative review of recommendations was conducted. All results were screened by two independent reviewers (LP and TAS) using prespecified inclusion and exclusion criteria. Outcomes of interest were extracted into Excel, with all conflicts resolved through discussion/consensus. Tables displayed outcomes and research topics first by year, then by registry.

Prospero registration number

CRD42023402431.

Weiterlesen

]]>409Sun, 25 Jan 2026 18:42:10 +0000Network pharmacology-based elucidation of the regulatory mechanism of Solanum lyratum (Bai Ying) against psoriasis via the IL-17A/STAT3 axis: Molecular docking and HaCaT cell validation.https://www.psoriasis-news.de/articles.html/1_articles/network-pharmacology-based-elucidation-of-the-regulatory-mechanism-of-solanum-lyratum-bai-ying-against-psoriasis-via-the-il-17astat3-axis-molecular-docking-and-hacat-cell-validation-r408/BackgroundPsoriasis affects approximately 2% of the global population, with the IL-17A-STAT3 pathway mediating abnormal keratinocyte proliferation and inflammatory amplification. Solanum lyratum (Bai Ying) has long been used for skin disorders, and its steroidal alkaloids have anti-inflammatory potential, though the mechanisms remain unclear.

Objective

To elucidate the molecular basis and cytological efficacy of S. lyratum steroidal alkaloids in exerting anti-psoriatic effects via the IL-17A/STAT3 axis.

Methods

HPLC-MS-QTOF, network pharmacology, molecular simulation, and a HaCaT cell model with STAT3-siRNA assays were employed.

Results

Eighteen components were identified; steroidal alkaloids showed high affinity for STAT3 and IL17RA. S. lyratum (5-40 μg/mL) enhanced cell viability, inhibited p-STAT3 (IC50 = 14.30 μg/mL), and attenuated inflammatory responses and keratinocyte proliferation.

Conclusion

S. lyratum steroidal alkaloids exert dual-targeted blocking effects on the IL-17A/STAT3 axis, supporting it as a potential therapeutic candidate for psoriasis.

Weiterlesen

]]>408Sun, 25 Jan 2026 18:42:10 +0000Beyond the skin: Lived experiences and coping strategies of psoriasis patients in Malaysia.https://www.psoriasis-news.de/articles.html/1_articles/beyond-the-skin-lived-experiences-and-coping-strategies-of-psoriasis-patients-in-malaysia-r407/BackgroundPsoriasis is a chronic autoimmune skin condition that significantly impacts an individual's quality of life, resulting in physical discomfort, psychological distress, and compromised social well-being. However, there is limited understanding regarding the challenges faced by patients in Malaysia. This study examines the lived experiences of patients with psoriasis in Malaysia, focusing on the emotional, social, financial, and treatment-related challenges they face, as well as the coping mechanisms they employ.

Methods

A qualitative, phenomenological approach was employed among members of the Psoriasis Association Malaysia. Purposive sampling was used to recruit adult participants who were capable of participating in the online interview. Data collection involved the use of Google Forms, which included the Malay version of the Dermatology Life Quality Index questionnaire, supplementing the qualitative findings. This was followed by semi-structured online interviews conducted via video conferencing. Thematic analysis was conducted using NVivo version 14, and descriptive analysis was performed using SPSS version 28.

Result

This study involved 30 respondents with a mean age of 44 years diagnosed with psoriasis. The mean (SD) for the duration of illness is 21.3 (11.8) years. About 70% respondents reported that psoriasis had a moderate to very high impact on their quality of life. Thematic analysis has identified six major themes, including physical devastation, emotional burden, disruption in social functioning, treatment hurdles and advancements, financial barriers, and behavioral adaptation.

Conclusion

Psoriasis imposes complex challenges that extend beyond physical symptoms, affecting emotional well-being, social interactions, financial stability, and treatment struggles. In response to the various challenges that arose, respondents developed behavioral adaptations to achieve a better quality of life. Framed within the biopsychosocial model, the findings emphasize the need for a holistic, patient-centred approach to psoriasis care that integrates medical treatment with psychological support and social interventions to improve overall quality of life.

Weiterlesen

]]>407Sun, 25 Jan 2026 18:42:10 +0000Unsaturated Fatty Acid Metabolic Reprogramming in Psoriatic Skin Drives Inflammation and Predicts Response to Biologic Therapy.https://www.psoriasis-news.de/articles.html/1_articles/unsaturated-fatty-acid-metabolic-reprogramming-in-psoriatic-skin-drives-inflammation-and-predicts-response-to-biologic-therapy-r406/PurposePsoriasis is frequently associated with dyslipidemia, yet the role of specific unsaturated fatty acid (UFA) metabolic pathways in disease pathogenesis and treatment response remains poorly understood. This study aimed to characterize the landscape of UFA metabolic reprogramming in psoriasis and evaluate its clinical relevance for predicting response to biologic therapy.

Patients and methods

We performed an integrated multi-omics analysis incorporating transcriptomic data from human psoriatic lesions, single-cell RNA sequencing, and lipidomic profiling. Gene set variation analysis (GSVA) was used to evaluate UFA pathway activity. Logistic regression and LASSO were employed for biomarker selection and predictive modeling.

Results

We identified eight significantly dysregulated UFA metabolic pathways in psoriatic lesions, six of which were associated with key pathogenic processes in psoriasis. All pathways were reversibly modulated by biologic agents targeting TNF-α, IL-12/23, and IL-17A. We derived a three-gene biomarker signature (PLA2G4D, PLA2G4A, and FADS2) that robustly predicts response to IL-12/23 inhibition prior to treatment initiation (AUC = 0.902). Single-cell RNA sequencing revealed keratinocytes as the primary cellular contributors to UFA metabolism and identified an expanded PLA2G4D-high keratinocyte subpopulation in psoriatic skin, which was associated with the accumulation of Lysophosphatidylcholine (LysoPC) and Lysophosphatidylethanolamine (LysoPE).

Conclusion

Our findings elucidate the pathway-level metabolic basis of psoriasis inflammation and provide a clinically applicable tool for predicting response to biologic therapy. The results highlight the importance of UFA metabolic reprogramming in psoriatic pathogenesis and offer new avenues for treatment personalization.

Weiterlesen

]]>406Mon, 29 Dec 2025 19:17:49 +0000Preparation of Tanshinone IIA and glycyrrhetinic acid emulsion and preliminary study on its anti-psoriasis efficacy.https://www.psoriasis-news.de/articles.html/1_articles/preparation-of-tanshinone-iia-and-glycyrrhetinic-acid-emulsion-and-preliminary-study-on-its-anti-psoriasis-efficacy-r405/AimThe current work highlighted the preparation method of Tanshinone IIA, Glycyrrhetinic acid Emulsion with eutectic (GT-eEmu) and investigated its effectiveness in the internal and external treatment of psoriasis.

Materials & methods

The optimal prescription ratios of the emulsions were screened based on single-factor and orthogonal experiments, in which the appearance, particle size, centrifugal stability, and placement stability of the emulsion were used as indicators. On this basis, the maximum drugs loading was determined and optimized by D-optimal. Then the gloss, consistency, uniformity, spreading, and centrifugal stability of the emulsion gel were used as indicators to screen the best preparation method of the emulsion gel. The gastrointestinal stability of GT-eEmu and the original drug was evaulated by the artificial gastrointestinal fluid test, while the irritation to the the gastrointestinal mucosa was investigated after treatment. In addition, the skin permeability and skin side effects of the preparation were studied. Finally, the therapeutic effects of various preparations on psoriasis in mice were studied based on PASI scores, HE pathological sections and the expression of SOCS1 and STAT3.

Results

The best optimized prescription of GT-eEmu was: oil phase 7%, emulsifier 4.5%, and emulsification temperature 60 ℃, where the drug loading of TSN IIA and GA were 0.17 and 0.70 g·L- 1. The best preparation method for GT-eEmu-Gel was to add carbomer 980 with 6% gel matrix to the emulsion prepared by the optimized method, followed by mixing with triethanolamine and adjusting the pH to 6.0-7.0 to prepare a 0.5% carbomer matrix emulsion. The gastrointestinal stability experiment showed that the addition of eutectic ingredients did not cause significant irritation to the gastrointestinal tract, while the good permeability and sustained release of GT-eEmu-Gel were shown by in vitro release assays and the emulsion gel form could further reduce the irritation of eutectic to the skin. Finally, imiquimod-induced psoriasis animal model experiments indicated that GT-eEmu and its gel could reduce the degree of skin lesions and histopathological changes in model mice, and decrease the average expression of SOCS1 and STAT3, which indicated these preparation had therapeutic effects on psoriasis. Additionally, the "internal and external treatment" group had the best effect compared with the oral-only group, while there was a significant difference (P < 0.01) compared with the model group.

Conclusion

The preparation process of GT-eEmu and GT-eEmu-Gel is stable and quality-controlled, which can improve the oral bioavail ability of both drugs to different degrees and reduce the irritation to the skin. The results showed that they have certain therapeutic effects on psoriasi, which can be safely administered orally and applied externally on the skin. At the same time, compared with the single treatment, the "internal and external combined treatment" method was the most effective, which indicates the concept of "internal and external combined treatment" method has practical significance.

Weiterlesen

]]>405Mon, 29 Dec 2025 19:17:49 +0000Prevalence of tobacco smoking and its association with disease severity and psoriatic arthritis among patients with nail psoriasis in China: a cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/prevalence-of-tobacco-smoking-and-its-association-with-disease-severity-and-psoriatic-arthritis-among-patients-with-nail-psoriasis-in-china-a-cross-sectional-study-r404/IntroductionNail psoriasis is a common, treatment-refractory manifestation of psoriasis. Smoking is a key environmental factor implicated in nail and articular psoriasis. While smoking's association with cutaneous psoriasis is well-studied, its relationship with nail psoriasis remains less explored.

Objective

The primary objective of this study was to investigate the impact of smoking on the severity of nail psoriasis and arthritic psoriasis in patients with nail psoriasis.

Methods

Data from 1044 nail psoriasis patients within a population-based registry in China were analyzed. We assessed associations of smoking status and intensity with sociodemographics, disease severity and dermatology quality of life measures (including PASI, BSA, DLQI, and PEST scores), and PsA diagnosis. Analyses used SPSS 29.0; p < 0.05 defined significance.

Results

The current smoking rate among patients with nail psoriasis is 34.6%, which is much higher than the current smoking rate among patients without nail psoriasis (20.2%). The proportions of the three different smoking intensities are also much higher than those among patients without nail psoriasis. Current smoking affects the total nail involvement count in patients with nail psoriasis, and severe smoking affects both the total nail involvement count and the nails with > 90% area involvement count in these patients. However, we found that smoking intensity was negatively correlated with DLQI scores in nail psoriasis, which is contrary to previous studies on plaque psoriasis. Spearman's correlation analysis revealed that smoking intensity and smoking index were positively associated with total nail involvement count and individual nails > 90% with area involvement count. In the regression analysis for PSA, the OR for current smokers was 0.57 (95% CI: 0.35-0.92) compared to non-smokers, and the OR for severe smokers was 0.37 (95% CI: 0.15-0.90) compared to mild smokers.

Conclusion

Patients with nail psoriasis have higher smoking rates and smoking intensity compared to those without nail psoriasis. The total nail involvement count was higher in current smokers than in non-smokers. Smoking intensity was positively associated with total nail involvement count and individual nails with > 90% area involvement count. Current smoking was a negative associated factor for PEST risk level. Both current smoking and severe smoking were negative associations with the presence of psoriatic arthritis.

Weiterlesen

]]>404Mon, 29 Dec 2025 19:17:49 +0000Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/understanding-cumulative-life-course-impairment-in-canadian-patients-with-psoriasis-r403/Weiterlesen

]]>403Sat, 27 Dec 2025 18:01:44 +0000Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.https://www.psoriasis-news.de/articles.html/1_articles/assessing-internal-construct-validity-of-dapsa-and-dapsa28-in-psoriatic-arthritis-a-european-observational-study-using-confirmatory-factor-analysis-and-additional-psychometric-testing-r402/ObjectivesThe Disease Activity index for Psoriatic Arthritis (DAPSA) was developed to assess disease activity in patients with psoriatic arthritis (PsA). A modified version, DAPSA28, uses 28 joints instead of 66/68. This study evaluated key psychometric properties of DAPSA and DAPSA28.

Methods

Data from 1865 patients with PsA in the European Spondyloarthritis (EuroSpA) Research Collaboration Network, having DAPSA and DAPSA28 scores at baseline and follow-up, were analysed. Tests included assessment of internal construct validity by scree plots, confirmatory factor analysis (CFA) and structural equation modelling (SEM), supplemented by tests of differential item functioning (DIF) and evaluation of internal consistency reliability by Cronbach's α (CA). A subset of 625 patients was used for most analyses, except descriptive statistics, correlation matrix and CA.

Results

One-dimensional CFA models for DAPSA and DAPSA28 showed acceptable model fit at baseline (root mean square error of approximation, RMSEA: 0.020, 0.034). However, model fit at 6 months follow-up was poor (RMSEA: 0.057, 0.063). SEM combining baseline and follow-up data could not identify an acceptable model fit. DIF was found for sex and country. CA indicated acceptable internal consistency (DAPSA: 0.65; DAPSA28: 0.63). Heterogeneity across countries was observed.

Conclusions

Overall, the model fit was acceptable across model fit statistics, supporting internal construct validity, but some evidence of misfit at country level was disclosed. Our findings support acceptable internal consistency reliability, but DIF was found for sex and country. Based on mixed results of model fit and DIF, further investigation of these and other PsA disease activity measures is warranted.

Weiterlesen

]]>402Sat, 27 Dec 2025 18:01:44 +0000To Explore the Mechanism of Cuproptosis in Psoriasis Based on Bioinformatics and in vivo Experiments.https://www.psoriasis-news.de/articles.html/1_articles/to-explore-the-mechanism-of-cuproptosis-in-psoriasis-based-on-bioinformatics-and-in-vivo-experiments-r401/PurposeTo explore the mechanism of cuprotosis in psoriasis, screen cuprotosis related genes (PDCRGs) in psoriasis, and provide new targets for precise diagnosis and treatment of psoriasis.

Material and methods

Integrate bioinformatics analysis and experimental validation. Firstly, based on the GEO database (GSE161683, GSE166388, GSE277173), differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA) in psoriasis were screened; Identification of differential cuprotosis related genes (PDCRGs) in psoriasis using a self built cuprotosis gene database (1098 CRGs); Screen key PDCRGs through PPI network, machine learning, and ROC analysis. Subsequently, a mouse model of psoriasis induced by imiquimod (IMQ) was constructed, and gene expression, copper ion levels, inflammatory factors, and oxidative stress factors were validated using qPCR, Western blot, immunohistochemistry, fluorescence, and ELISA.

Results

Thirty-four PDCRGs were identified, among which STAT1, DLD, GBP1, CXCL10, PDHB, and LIAS are Hub genes. Machine learning and ROC analysis further identified APOL6, CD274, and LIAS as key diagnostic biomarkers. PDCRGs are significantly enriched in the TCA cycle, copper ion transport, and glucose metabolism pathways. The levels of FDX1 and serum copper ions were increased in the skin lesions of psoriasis mice, accompanied by upregulation of TCA cycle key proteins and PDCRGs expression; Copper overload triggers oxidative stress and inflammation cascade.

Conclusion

APOL6, CD274, and LIAS were screened as cuprotosis markers in psoriasis. Overexpression of these PDCRGs in psoriasis model mice can promote copper ion accumulation and interfere with the TCA cycle, increase oxidative stress and inflammation levels, and ultimately lead to the occurrence of psoriasis. Therefore, targeted intervention of cuprotosis is of great significance for the clinical treatment of psoriasis.

Weiterlesen

]]>401Sat, 27 Dec 2025 18:01:44 +0000Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis - A Pilot Study on a Mouse Model.https://www.psoriasis-news.de/articles.html/1_articles/antibodies-targeting-gasdermin-e-as-a-potential-therapeutic-option-for-psoriasis-a-pilot-study-on-a-mouse-model-r400/BackgroundPsoriasis is a frequent and complex dermatosis of uncertain origin. A few years ago, a family of gasdermin proteins was implicated in psoriasis pathogenesis. Although the number of therapeutic options for psoriasis is growing, considering the burden of the disease, treatment personalization, and the possibility of side effects or loss of the drug's efficacy, it is important to seek new therapeutic targets.

Objective

The aim of this study was to assess the efficacy of antibodies against gasdermin E (GSDME) in the treatment of psoriatic lesions.

Methods

The study involved 30 male BALB/c mice, 8 weeks old. 5% imiquimod cream was applied topically on the skin to induce psoriatic lesions. The next day after the psoriatic lesions appeared, the antibodies were administered. Mice from the study group received the rabbit polyclonal anti-GSDME antibody intravenously or intraperitoneally. The control group was administered sterile 0.9% saline solution.

Results

The injection of anti-GSDME antibodies to mice with imiquimod-induced psoriasis resulted in the resolution of skin lesions, whereas the injection of saline to the control group did not result in significant changes.

Conclusion

Antibodies targeting GSDME seem to be promising therapeutic agents in psoriasis; however, their utility has to be confirmed in future studies.

Weiterlesen

]]>400Sat, 27 Dec 2025 18:01:44 +0000Association of Sociodemographic Factors and Mental Health Utilization for Psoriasis Patients in the Medical Expenditure Panel Survey.https://www.psoriasis-news.de/articles.html/1_articles/association-of-sociodemographic-factors-and-mental-health-utilization-for-psoriasis-patients-in-the-medical-expenditure-panel-survey-r399/BackgroundPsoriasis is associated with increased psychiatric comorbidity, yet patterns of mental health care use and spending remain unclear.

Objective

To characterize use and expenditures for outpatient mental health services and psychotropic medications among U.S. persons with psoriasis and identify sociodemographic disparities.

Methods

Cross-sectional analysis of 2,123 participants with psoriasis in the 2005-2022 Medical Expenditure Panel Survey. Negative binomial and two-part models examined associations between sociodemographic characteristics and mental health care utilization and spending.

Results

Higher education and income levels were associated with fewer psychiatrist visits, but lower-income groups had greater utilization overall. Men spent more on psychotropic medications than women. Racial minorities had lower medication spending than White patients. Medicare coverage was linked to greater total expenditure compared to private insurance.

Limitations

Psoriasis severity was unavailable. International Classification of Diseases-based identification may undercount cases.

Conclusion

Substantial sociodemographic and insurance disparities persist in mental health care use and spending among psoriasis patients.

Weiterlesen

]]>399Sat, 27 Dec 2025 18:01:44 +0000